Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors

Balamurugan, Appathurai; Ahmed, Faruque; Saraiya, Mona; Kosary, Carol; Schwenn, Molly; Cokkinides, Vilma; Flowers, Lisa; Pollack, Lori A.

doi:10.1002/cncr.23746

Cited by 34 publications

(29 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[9][10][11] The rising incidence of these cancers in parallel with the high prevalence of HPV infection has been widely reported and attributed to factors such as changing sexual practices 12 and cross-infection at multiple anatomic sites. [15][16][17] The increased risk of SPM in other head and neck sites also has been found in patients with HPV-related oropharyngeal cancers. Recent studies have suggested an elevated risk of HPVrelated SPMs in survivors of HPV-related cancers.…”

Section: Introductionmentioning

confidence: 91%

Elevated risk of human papillomavirus‐related second cancers in survivors of anal canal cancer

Nelson

Lai

2017

Cancer

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 91%

Elevated risk of human papillomavirus‐related second cancers in survivors of anal canal cancer

Nelson

Lai

2017

Cancer

View full text Add to dashboard Cite

show abstract

“…Previous studies suggest cervical cancer survivors have a greater risk of developing any subsequent malignancy, compared with other cancer survivors [3,4]. The elevated risk of subsequent malignancies among cervical cancer survivors has been attributed to increased cancer vulnerability due to infection with Human Papillomavirus (HPV), adverse effects of cancer treatment, including radiation therapy; and risky health behaviors among survivors, including cigarette smoking [5].…”

Section: Introductionmentioning

confidence: 99%

Cervical cancer survivors at increased risk of subsequent tobacco-related malignancies, United States 1992–2008

Underwood

Rim

Fairley

et al. 2012

Cancer Causes Control

View full text Add to dashboard Cite

Purpose-Persistent smoking among cancer survivors may increase their risk of subsequent malignancies, including tobacco-related malignancies. Despite these risks, nearly 40 % of women diagnosed with cervical cancer continue to smoke after diagnosis. This study describes the relative risk of developing any subsequent and tobacco-related malignancy among cervical cancer survivors.Methods-We examined data from the year 1992 to 2008 in 13 Surveillance, Epidemiology and End Results registries. We calculated the standardized incidence ratio (SIR) and 95 % confidence limits (CLs) for all subsequent and tobacco-related malignancies among cervical cancer survivors. Tobacco-related malignancies were defined according to the 2004 Surgeon General's Report on the Health Consequences of Smoking. For comparison with cervical cancer survivors, SIRs for subsequent malignancies were also calculated for female survivors of breast or colorectal cancers.Results-The SIR of developing a subsequent tobacco-related malignancy was higher among cervical cancer survivors (SIR = 2.2, 95 % CL = 2.0-2.4). Female breast (SIR = 1.1, 95 % CL = 1.0-1.1) and colorectal cancer survivors (1.1, 1.1-1.2) also had an elevated risk. The increased risk of a subsequent tobacco-related malignancy among cervical cancer survivors was greatest in the first 5 years after the initial diagnosis and decreased as time since diagnosis elapsed.Conclusion-Women with cervical cancer have a two-fold increased risk of subsequent tobacco-related malignancies, compared with breast and colorectal cancer survivors. In an effort to decrease their risk of subsequent tobacco-related malignancies, cancer survivors should be targeted for tobacco prevention and cessation services. Special attention should be given to cervical cancer survivors whose risk is almost twice that of breast or colorectal cancer survivors.

show abstract

“…9 With the advent of HPV vaccines, cervical neoplasms of the HPV types included in the vaccine are not the only types of neoplasms that are prevented 16 ; the incidences of VAIN and vulvar intraepithelial neoplasia are also significantly reduced. 17 Using SEER data (1992-2004), Balamurugan et al 18 found that there was a significantly elevated risk for subsequent in situ cancers of the vagina and vulva (standardized incidence ratios [SIRs] of 53.8 and 6.6, respectively) and invasive vaginal and vulvar cancers (SIRs of 29.9, and 5.7, respectively) among cervical cancer survivors. Whether the subsequent vaginal and vulvar cancers and precursors arose from persistent or new HPV infections requires comparison between cervical and subsequent neoplasms.…”

mentioning

confidence: 99%

Human papillomavirus in vaginal intraepithelial neoplasia

Chao

Chen

Hsueh

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

There are limited data on the prevalence and distribution of human papillomavirus (HPV) genotypes in vaginal intraepithelial neoplasia (VAIN). We sought to clarify this issue in a series of 450 VAIN cases with a confirmed diagnosis between 1990 and 2006. HPV genotyping was performed using paraffin-embedded specimens and polymerase chain reaction (PCR)-based methods. Multiple HPV types were validated by E6 type-specific PCR and direct sequencing. The HPV genotypes of the vaginal and cervical neoplasms were compared for those with incident VAIN and a history of previous/concomitant cervical neoplasms. Ki-67 was performed for supporting diagnosis of VAIN. Of these 450 VAIN cases (median age, 59 years; range, 19-93), two with missing paraffin blocks and 54 with poor DNA quality were excluded. HPV was detected in 273/394 (69.3%) VAIN, and multiple infections were found in 17.9% of HPV-positive samples. The leading types were HPV16 (35.5%), HPV58 (9.9%), HPV52 (9.9%), HPV39 (8.4%), HPV33 (7.3%) and HPV53 (7.0%). Among the 156 cases with a history of previous cervical neoplasia, 29.0% had concordant HPV genotypes, while synchronous VAIN samples (n 5 49) were more likely to harbor concordant genotypes (58.7%) with the concomitant cervical neoplasm (p 5 0.0003). Whether those HPV types in the incident VAIN lesions had existed in the vaginal epithelium at the time of the previous cervical neoplasia or a new acquisition needs to be clarified in prospective follow-up studies.The natural history of invasive vaginal cancer and preinvasive lesions (vaginal intraepithelial neoplasia [VAIN]) has been minimally investigated compared to invasive cervical cancer and cervical intraepithelial neoplasia (CIN). 1,2 Many previous research efforts have indicated that invasive vaginal cancer and VAIN share common risk factors with cervical neoplasms, including the number of lifetime sexual partners, smoking and infection with human papillomavirus (HPV). 1,3,4 Previous radiation exposure, a previous history of cervical neoplasms, diethylstilbestrol exposure and an immune-compromised state were also associated with an increased risk of vaginal cancer and VAIN. 1,[4][5][6][7] Previous studies regarding HPV types in VAIN and vaginal cancer or comparisons of HPV types between incident vaginal and previous cervical lesions were limited by small sample sizes and inconsistent conclusions. 3,4,[8][9][10][11][12][13][14][15] Smith et al. 8 published a systemic review of 725 abstracts, in which the HPV detection rates among 166 cases of VAIN2/3 and 66 cases of VAIN1 were 92.6% and 98.5%, respectively. Another systemic review of 22 U.S. studies found HPV16/18 to be the predominant type in VAIN3 (n ¼ 97, 65.1%). 10 A meta-analysis of 93 studies 9 including 298 cases of VAIN from four continents noted that HPV testing was positive in 100% of VAIN1 and 90.1% of VAIN2/3. In VAIN2/3 (n ¼ 191), the most common HPV types were HPV16 (57.6%), HPV 18 (6.9%) and HPV 58 (5.9%). 9 With the advent of HPV vaccines, cervical neoplasms of the HPV types included in th...

show abstract

Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors

Cited by 34 publications

References 31 publications

Elevated risk of human papillomavirus‐related second cancers in survivors of anal canal cancer

Elevated risk of human papillomavirus‐related second cancers in survivors of anal canal cancer

Cervical cancer survivors at increased risk of subsequent tobacco-related malignancies, United States 1992–2008

Human papillomavirus in vaginal intraepithelial neoplasia

Contact Info

Product

Resources

About